A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem (Sodium Oxybate) [JZP-6; Jazz Pharmaceuticals] in Subjects With Fibromyalgia.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Xyrem (Sodium Oxybate) [JZP-6; Jazz Pharmaceuticals] in Subjects With Fibromyalgia.

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2015

At a glance

  • Drugs Sodium oxybate (Primary)
  • Indications Fibromyalgia
  • Focus Registrational; Therapeutic Use
  • Sponsors Jazz Pharmaceuticals Inc
  • Most Recent Events

    • 16 Jun 2010 Results presented at 11th Annual Congress of the European League Against Rheumatism (EULAR) 2010.
    • 16 Jun 2010 Results presented at 11th Annual Congress of the European League Against Rheumatism (EULAR) 2010.
    • 22 May 2010 Results have been presented at the 163rd Annual Meeting of the American Psychiatric Association (APA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top